Sage acted as transaction adviser to PolyPid on the North American commercialisation agreement LONDON, 3 September 2026 Sage is a specialist global life-sciences transaction advisory firm, is pleased to confirm that it acted as transaction adviser to PolyPid Ltd. (Nasdaq: PYPD) in connection with its exclusive commercial partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the United States and Canada for the prevention of abdominal colorectal su